FDA Just Published the Development Standard for Generic Semaglutide. That Is Not Permission to Sell It.

On July 28, 2026, the FDA published 17 revised draft product-specific guidances covering peptide drug products, semaglutide, tirzepatide, and liraglutide among them. The Federal Register notice ran the next day and opened a comment period through September 28, 2026.

Within about a week the version circulating through the weight-loss and peptide trade had changed shape. The agency was said to be clearing the way for generic Ozempic. Suppliers were said to be positioned. That reading is wrong, and the operators who act on it are the ones who end up explaining their marketing copy to a federal grand jury.

A product-specific guidance is a document FDA writes for one audience: a generic manufacturer preparing an abbreviated new drug application. It describes the analytical and bioequivalence data the agency expects to see in that application. It approves nothing. It clears nothing. It confers no legal status on any product currently sitting in a clinic refrigerator or a fulfillment warehouse.

FDA told manufacturers how to build an application. It did not tell anyone they could sell a product. The distance between those two facts is where the federal cases get built.

Key Takeaways

• FDA's July 28, 2026 revised PSGs are development recommendations for ANDA sponsors under 21 U.S.C. § 355(j), not approvals of any product.
• No generic semaglutide or tirzepatide has final FDA approval. Anything sold in the United States under that label is an unapproved new drug.
• Selling an unapproved or misbranded drug violates 21 U.S.C. § 331, a felony under § 333(a)(2) when intent to defraud or mislead is present.
• The revised PSGs give prosecutors a published federal standard for peptide sameness, which cuts directly against gray-market same molecule marketing claims.
• In Florida, receiving prescription drugs from an unauthorized distributor is a felony under Fla. Stat. § 499.0051, and South Florida is among the most active federal districts on peptide and compounded-drug enforcement.

What FDA Actually Published

Seventeen revised draft PSGs, covering peptide drug products indicated for obesity, type 2 diabetes, osteoporosis, macular degeneration, and other conditions. The list includes semaglutide products referencing Ozempic and Wegovy, tirzepatide products referencing Mounjaro and Zepbound, liraglutide products referencing Victoza and Saxenda, plus calcitonin salmon, dasiglucagon hydrochloride, glucagon, pegcetacoplan, teriparatide, and vosoritide.

The revisions address five areas of generic peptide development: submission of recombinantly, synthetically, or semi-synthetically produced peptides through the ANDA pathway; innate immune response testing; impurity thresholds; higher-order structure assessment; and biological activity assessment.

Seventeen documents, all still in draft. They describe the analytical and bioequivalence data an application must contain. None of them authorizes a sale.

FDA simultaneously withdrew its May 2021 guidance, ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin, on the stated basis that it no longer reflects the agency's current scientific thinking. A replacement is on the CDER guidance agenda for later in 2026.

All 17 documents remain in draft. Comments close September 28, 2026.

What a PSG Is, and What It Is Not

This distinction is not academic. It is the whole case.

The generic drug approval pathway runs through 21 U.S.C. § 355(j). A sponsor files an ANDA, demonstrates sameness and bioequivalence to the reference listed drug, clears patent and exclusivity barriers, and receives approval. Only at the end of that sequence does a lawful generic exist.

Semaglutide is not there. A tentative approval has been reported for at least one semaglutide ANDA, and a tentative approval is a finding that the application meets FDA's scientific standards while patent or exclusivity barriers block marketing. It is not authorization to sell. Tirzepatide has no approved generic at all.

"This distinction is not academic. It is the whole case."— Aaron M. Cohen, AMC Defense Law

So the legal position on August 23, 2026 is unchanged from what it was on July 27. Any product offered for sale in the United States as generic semaglutide or generic tirzepatide is an unapproved new drug under 21 U.S.C. § 355. Introducing it into interstate commerce is a prohibited act under 21 U.S.C. § 331.

Compounding does not fix this either. FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, and the shortage-based exemptions that carried the compounded GLP-1 market in 2024 and 2025 have narrowed considerably. Sections 503A and 503B are exemptions with conditions, not a parallel drug approval system.

The Part That Helps the Government

Here is what the industry commentary has missed, and it is the reason this guidance package matters to a defense lawyer more than to a compliance consultant.

For years the gray-market pitch has been some version of "it is the same molecule." That claim was hard to test. It lived in the space between marketing puffery and technical assertion, and it was awkward to cross-examine because there was no published federal yardstick for what sameness in a peptide actually requires.

A published federal standard for peptide sameness turns an untestable sales claim into a measurable one. That is what converts a regulatory file into an intent case.

There is now. FDA has written down, product by product, what characterization is required to establish that a peptide is the same as its reference drug: impurity thresholds, higher-order structure, innate immune response testing, biological activity. A seller who told customers his research-grade tirzepatide was equivalent to Zepbound, and who cannot produce a single one of those analyses, is no longer making an untestable claim. He is making a claim measurably contradicted by a federal standard he could have read.

That converts a strict liability regulatory problem into an intent case. Under 21 U.S.C. § 333(a)(1), a first violation is a misdemeanor requiring no proof of knowledge. Under § 333(a)(2), the same conduct is a three-year felony when committed with intent to defraud or mislead. Published guidance is how the government shows what a defendant should have known.

Exposure and Charges

The statutes stack the way they always do in this space.

Prohibited acts under 21 U.S.C. § 331, including introduction of an unapproved new drug and of a misbranded drug, with penalties under § 333. Marketing claims that outrun the regulatory reality support wire fraud under 18 U.S.C. § 1343. Multi-party sourcing and sales arrangements, which is nearly every peptide distribution structure, draw conspiracy exposure under 18 U.S.C. § 1349. Any billing touchpoint with Medicare, Medicaid, or TRICARE brings health care fraud under 18 U.S.C. § 1347 and the Anti-Kickback Statute, 42 U.S.C. § 1320a-7b, into the case. Imported product adds smuggling and entry-by-false-statement counts under Title 18.

Florida Reaches the Receiving End of the Supply Chain

Florida reaches the receiving end of the supply chain, which is the piece most operators do not see coming. Under Fla. Stat. § 499.0051, knowingly purchasing or receiving a prescription drug from an unauthorized distributor is a felony. The clinic that bought from a supplier it never verified is exposed under state law independent of anything federal, and the state file frequently becomes the roadmap for the federal one.

Prescribing structure is the second Florida issue. Where the ordering practitioner never conducted a good faith examination, or where an unlicensed person directed the prescribing, unlicensed practice of medicine under Fla. Stat. § 458.327 is a third-degree felony, and Florida prosecutors file it against aesthetic and weight-loss providers rather than leaving it to the Department of Health.

The Southern District of Florida and FDA Office of Criminal Investigations both maintain a heavy footprint here. A Boca Raton or Miami weight-loss practice operating on a national supplier's compliance assurances is relying on a document that has never been tested against the district it will be tested in.

The Mistakes That Turn a Compliance Question Into a Case

Reading a guidance headline as a green light. FDA published development standards for manufacturers. Nothing in those 17 documents authorizes a clinic, a telehealth platform, or a peptide seller to do anything.

Updating the website after the inquiry starts. Pulling product pages, revising treatment menus, or altering supplier records once FDA or a U.S. Attorney's Office makes contact is obstruction under 18 U.S.C. § 1519, a twenty-year felony that has sunk otherwise defensible matters.

Producing everything in response to a subpoena. A federal grand jury subpoena is the beginning of a negotiation about scope, not an order to hand over the practice management system.

Assuming the prescriber carries the risk alone. The government builds these cases at the ownership, MSO, and marketing layer, because that is where intent is documented.

Where the Defense Work Actually Happens

Before charges. A federal investigation defense lawyer engaged at the warning letter, civil investigative demand, or subpoena stage can establish whether the client is a witness, a subject, or a target, and can put sourcing documentation, prescribing protocols, and the actual regulatory history in front of a prosecutor before agents build a timeline without it. Employees contacted by federal agents need independent counsel, not company counsel, and that separation has to happen early to mean anything.

Common Questions

Facing an FDA Inquiry, a Warning Letter, or a Grand Jury Subpoena?

AMC Defense Law represents peptide and pharmaceutical companies, compounding pharmacies, telehealth platforms, med spa and weight-loss clinic owners, MSO operators, physicians, nurse practitioners, and physician assistants in federal investigations and prosecutions involving unapproved and misbranded drugs, health care fraud, and related conduct. The firm's South Florida federal criminal defense practice is based in Boca Raton and handles matters throughout Florida and nationwide.

If FDA Office of Criminal Investigations, a state board, or a U.S. Attorney's Office has contacted you or your business, speak with a federal criminal defense attorney before you respond or produce anything.

If FDA Office of Criminal Investigations, a state board, or a U.S. Attorney's Office has contacted you or your business, speak with a federal criminal defense attorney before you respond or produce anything. Contact the firm for a confidential consultation.

If you or your loved ones have been arrested or are under federal investigation, call Aaron M. Cohen, 24 hours a day to get help.